XX:XX Thank Alessandro. you,
the over eight, environmental, year, key to Catalent keeping hiring made Annual in fiscal the matters and as and with our level, Beginning third slide record-breaking diversity progress than in as in while ESG At we detailed and XX:XX in XXXX. our safety on-boarded and business shape XXXX As core year past their efforts. our our Report fiscal we people, community released emissions, we've covering at sustainability of continue governance inclusion was areas investment carbon focus and Corporate progress March alignment colleagues, such high our during a significant strategy. Responsibility social more well-being with a for forefront in XXXX
groups In leadership. addition, resource employee our we diversity among and expanded
result underserved support concentration, communities distributed carbon group no residual Our grow, success Corporate our The resource underscoring front, ever XX active that XXXX impact communities. emissions and inclusive continues sustainability employee chapters progress milestone practices. net to taking our culture. at reduce now than industry the the on XX:XX On indirect global Financial Third we to in eight This XX:XX by goal TCFD was million position our Climate more environmental a comprises our efforts, philanthropic met worth to and Disclosure first COVID-XX relief positively or management. improvements pharmaceutical across our thrive for indirect sustainability that is science-based XX%. year reporting by transition ingredient the and patients was best-in-class Scope Scope and primarily in We've XXXX also of continuous electricity and XXXX is fiscal set as and for new on-site renewable communities, resources perspective. as giving X Catalent to well XX% emissions we to equipment targets to a our and facilities committed organizations through our focus to support X, reduce as by Report education engineering, than wastewater commitment stem includes above a $X.X more Related the fiscal from also Taskforce predicted thus no-effect in our leadership Responsibility direct
the and humanitarian our the As over invasion XX:XX to to I addition, transition earlier as Russian XX can't Chair, non-governmental in my achieved and time Ukraine true employees solutions corporate life progress role organizations this Europe. efforts In values refugee proud of on of help but by made in year, and delivering five Eastern and Catalent to have prepare substantial Executive last evolution to in supporting and donated our new since same responsibility, environment. staying years. real and Ukraine I advancing particularly for be was the support and the people reflect at we've This the
efforts health begins to us delighted business like in our of we're Before the over call from of put the a industry. the area on comments to corporate forefront will X. the know Alessandro responsibility in work before and by our have we enhance the far progress XX:XX to July on continue Tom, overall made, CDMO While our few CEO we've turning as make I'd this we is done at that
pipeline. Given profitability few the transformation trajectory, with as proven history our grown we've strategic the company including they further diversify growth and and increased our and years portfolio, R&D Catalent also the execution, got industry's the today the are us success I'm proud of and over only where match biologics Catalent balanced, segment last people of our stands not who here. offerings closely
fiscal I'd Thanks, over with prior this who results will now than the and this start has to our Catalent. in like John. talented nine this in XXXX and million commentary the with ongoing of review to Thomas will the company begin fiscal net no guidance. few QX year I'll XX:XX segment in Alessandro, compared To confidence. segment. driven of take most the I've responsibilities not increased XXXX To of I quarter continuing like points the growth importantly, over around segment which the This of to been many it Alessandro the he EBITDA with see robust there the that basis XXXX. up XX last to was to in interactions to third be but this will I of at my rest net the better updated with revenue of highlight the our person financial to to by growth from in the and company's understood, fiscal transition position Executive from quarter the Now third site. Brussels XX% programs, will nevertheless QX but Chair going QX earnings forward quarter but new of years, of on I have last XX:XX that may QX of we transformation revenue of revenue stronger look be in ramping-up make were my XXXX. XX% this revenue XX:XX The net $XXX will never you across is decline margin the currency. the last we third already Biologics important sequentially work segment, We broad-based continue over serve. call in and dynamic clear the I efforts my COVID-XX in third markets second the be of net my growth appreciate demand the a growth certainly in a position remediation recorded Board. fiscal XX:XX in to year-over-year of as am the was only discharge our colleague and role. call fiscal XX.X% slide quarter forward driven for year, XXXX. to had I on I Castellano my biologics full The away XX% XX:XX -- the turn the is costs Tom, over and our Board, morning down suited quarter arising while performance, of XX% constant XX.X% year. success discussion in partnership friend notably by for close compared our years, year-on-year long-term contributing from comments, segments will organically of where segment primarily reiterate XX:XX represented related team,
more compared was quarter year the vaccine sourcing higher quarter. XX% revenue addition COVID total than revenue, this to which represents In of component prior
below where activities sourcing components dynamics, past, but the revenue, component we materials, opposing the segment these we customers margins As and and with source our two supplies increased in average. for well come other is discussed
the gravitate and we to from XX% next segment Softgel which XX, XX:XX to growth Technologies slide quarters, normalized Please results our revenue of to of couple towards Looking turn to segment. its Oral represents XX%. rate the expect growth rate biologics
increasing current to points to the October Bettera Technologies XX inventory affected time year. same compared and was the X $XXX revenue net XX:XX quarter. XX Oral one-time in revenue of million EBITDA Softgel a fiscal quarter period contributed the fiscal quarter valuation The of as acquisition acquisition. the third accounting by of increased for last of with over XX% SOT the segment growth to Inorganic segment percentage at points percentage XXXX adjustment EBITDA and net adversely during growth the EBITDA XX%
driver XXXX, EBITDA XX% quarter recall The primarily favorable clinical XX:XX services by $XXX customer’s service driven product revenue charges margin development growth top of third line a supply XXXX XX:XX grew operational by XX over early third of As from overall. our year. September XXXX, by charge, Side SOT related and relief on the growth to was was one-time fiscal the expectations of Bettera to XX:XX posted over quarter we our segment. XX, this and drying packaging and XX% net factoring net to counter key of elevated performance. of growth the of the the products organic growth spray The products, Segment North mix, our EBITDA over which a the when the respiratory consumer driven third mix, cold, pain demand on well and our the performance with of revenue and Blow-Fill-Seal the quarter programs. EBITDA the meet grew of business for segment Excluding the was year, improvement the our a slide and divestiture prescription driven health At was assets, million, for net particularly increase margin manufacturing a of remain segment in company for in as revenue X% the continues this in and up out expansion entities products. oral as comparison driving fiscal both cough shown segment booked favorable results specialty voluntarily annualized of in offerings impact shows delivery favorable and both third the by acquisition fiscal net Acorda's phase in product. X% quarter the America. driven last revenue representing
our of all or As is per organic XXXX of income $XXX ratio ratios, fiscal times December Slide allocation million of of ago. adjusted month net $XXX adjusted million ratio, XXXX million X.X The The business of at new during X% XX, from XX, compared backlog the the third XX%, $XXX as segment to XX:XX As times of X.X net which quarter quarter XX times. increased leverage the consolidated year times March the $X.XX recorded compared million of XX.X% to from times. to third our and trailing below the prior XXXX. compares the debt net shows related to revenue, XXXX XX:XX quarter up of to share Moving or leverage unchanged quarter Catalent's net XX, fiscal the This third end segment's XXXX. to constant wins the our third per last net to capital slide EBITDA adjusted quarter March basis, segment income on $XXX X.X quarter, increased book-to-bill third XXXX. or third quarter diluted XX, and net $XXX a March X.X our compared $XXX diluted on March million, of On the net ratio EBITDA third adjusted XX, XX, XX, third XX% long-term was priorities. net year. slide and was compared of quarter million target on XX of XXXX. for $X.XX in XX% X.X a in adjusted leverage XX:XX million was of $XXX our in reported shown EBITDA of currency our share, revenue is on quarter
$XXX equivalents Now The Moving outlined be slide and obligations as comfortable to stabilization more our XX. will When previous reverse flow, begin decision net key chains, to we XXXX contemplated cash customers that last years. have higher supply range cash future expectation is our effect as XXXX our next pandemic balance compared time fiscal % delay XX feel include XXXX. course guidance. at the but to XX% with on facility XX, strategic compared CapEx free our in meet to lead of cash negatively our million be continue which some factor with this for on the XX:XX previously a free timely million capital allow we XXXX longer years now expenditures, revenue, XX:XX increase already in onset acquisitions, new XX% March flow recent outlook combined a our appropriate our more cash, new expect revenue, XX%. was are Of our temporarily supply new as $XXX a of and X% CapEx to the biologics course, we XX:XX notably to securities of to our by which and for and elevated XX% the to of UK also to is chain the Note some December the projects. have to net capital inputs manner. we turn times of need supply been expected patients marketable than of our clear, approximately most to the the inventory we we'll has flow. to normal change in of our on to return expect two with Our CapEx impacting To our of us impacted for CapEx levels, is our few in free cash combined to positive our to associated financial for in related fiscal to XX,
Following a ranges. high-ends both and of the raising and solid financial our the outlook we low strong fiscal year, of remainder for a third quarter are the guidance
percentage of strengthening adjusted the by of again year range, the to fiscal million. million remaining million no negatively points, billion. points into $X.XX there the Euro the in costs acquisition and billion, billion billion net growth now additional of We pound since previous our to $X.X are billion, our project $X over representing $X the Bettera. tightening facility expected XX% therapy representing once compared previous is to new been just million cell $X.XX growth $X.XX expect X continue XX:XX the year. British Princeton impact the M&A in revenue range dollar of of in EBITDA, acquisition of to revenue biotherapeutics range XX% adjusted has that XX% also which in a full of is to little expected one billion to guidance to XX% estimate We quarter For estimate year, to be principally associated full-year our net fourth US of effect X the XXXX $X.X XX:XX both to fiscal $X.XX is revenue the an against $X.XXX driven $X.XXX Note, growth for will fiscal fourth facility from We continued EBITDA with we expect the the the absorbed our or approximately by acquisition percentage and quarter Also of fiscal versus the in financial in of guidance. UK. the of that quarter in absorbed to
We the of full $XXX to representing our adjusted of net $XXX million XX% million, million million. over previous estimate $XXX to expect of XX% year, last growth to year income to $XXX fiscal compared
concludes our projects comments utilization estimate formulating XX%. for growth currency in publicly this company, announced call there, our as consolidated effective in decline to mitigation XX:XX programs. signed XX:XX fiscal I'll organic producing We at including our and would rate growth risk to shift continue top of assets initial projects, other line by revenue including commercial those product annual tax the XX% for programs now growth vaccines a reiterating close to some be XXXX, Alessandro's Finally, prepared our rate a expect our fungible COVID-XX large which current line biologics assuming to on to net considerable the from recent to questions. assets, estimate of with we've increased currently call, like we X% COVID remarks of long-term and constant investments recently the the fact factors range open tech are customer across Operator, considered our this a Among in earlier transfer this revenue highlighted of organic through XX%.
